A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis.
Katie BechmanAnthony DalrympleCharles Southey-BassolsAndrew P CopeJames B GallowayPublished in: BMC rheumatology (2020)
Despite evidence to suggest a role in diagnosing RA and in detecting synovitis, the heterogeneity of studies included in this review limit our ability to draw robust conclusions. At present there are inadequate results to justify the routine use of CXCL13 as a biomarker in RA routine clinical practice.